eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
Share:
Send email
Share:
Original paper

Clinicopathological importance of immunohistochemical expression of OCT4, c-MYC and Ki-67 in colorectal cancer

Rabia Hursitoglu
1
,
Abdulkadir Yasir Bahar
1
,
Sezen Koçarslan
1
,
Gökmen Aktaş
2
,
Neslihan Kurtul
3
,
Emine Kılınç
1

  1. Department of Pathology, Kahramanmaras Sutcu Imam University, Kahramanmaras, Turkey
  2. Department of Oncology, Kahramanmaraş Sütçü İmam University School of Medicine, Kahramanmaras, Turkey
  3. Department of Radiation Oncology, Kahramanmaraş Sütçü İmam University School of Medicine, Kahramanmaras, Turkey
Pol J Pathol 2024; 75 (4):
DOI: https://doi.org/10.5114/pjp.2024.146463
Online publish date: 2024/12/30
Article file
- Clinicopathological importance.pdf  [2.68 MB]
Get citation
 
PlumX metrics:
 
1. Mattiuzzi C, Sanchis-Gomar F, Lippi G. Concise update on colorectal cancer epidemiology. Ann Transl Med 2019; 7: 609. DOI: 10.21037/atm.2019.07.91.
2. Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther 2020; 5: 22. DOI: 10.1038/s41392-020-0116-z.
3. Adam R, Haller DG, Poston G, et al. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer – an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol 2010; 21: 1579-1584.
4. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013; 501: 328-337.
5. Bradshaw A, Wickremsekera A, Tan ST, et al. Cancer stem cell hierarchy in glioblastoma multiforme. Front Surg 2016; 3: 21. DOI: 10.3389/fsurg.2016.00021.
6. Shipitsin M, Polyak K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 2008; 88: 459-463.
7. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006; 355: 1253-1261.
8. Chen C, Liu Y, Liu Y, Zheng P. The axis of mTOR-mitochondria-ROS and stemness of the hematopoietic stem cells. Cell Cycle 2009; 8: 1158-1160.
9. Rehman J. Empowering self-renewal and differentiation: the role of mitochondria in stem cells. J Mol Med (Berl) 2010; 88: 981-986.
10. Kim TI. Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer. World J Gastroenterol 2014; 20: 3835-3846.
11. Burkert J, Wright NA, Alison MR. Stem cells and cancer: an intimate relationship. J Pathol 2006; 209: 287-297.
12. Ram R, Brasch HD, Dunne JC, et al. The identification of three cancer stem cell subpopulations within moderately differentiated lip squamous cell carcinoma. Front Surg 2017; 4: 12. DOI: 10.3389/fsurg.2017.00012.
13. Featherston T, Yu HH, Dunne JC, et al. Cancer stem cells in moderately differentiated buccal mucosal squamous cell carcinoma express components of the renin–angiotensin system. Front Surg 2016; 3: 52. DOI: 10.3389/fsurg.2016.00052.
14. Itinteang T, Dunne JC, Chibnall AM, et al. Cancer stem cells in moderately differentiated oral tongue squamous cell carcinoma express components of the renin–angiotensin system. J Clin Pathol 2016; 69: 942-945.
15. Van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 2010; 10: 301-309.
16. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
17. O'Hagan RC, Ohh M, David G, et al. Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev 2000; 14: 2185-2191.
18. Strippoli A, Cocomazzi A, Basso M, et al. c-MYC expression is a possible keystone in the colorectal cancer resistance to EGFR inhibitors. Cancers (Basel) 2020; 12: 638. DOI: 10.3390/ cancers12030638.
19. Lee KS, Kwak Y, Nam KH, et al. c-MYC copy-number gain is an independent prognostic factor in patients with colorectal cancer. PLoS One 2015; 10: e0139727. DOI: 10.1371/journal.­pone.0139727.
20. Kakisako KE, Miyahara MA, Uchino SH, et al. Prognostic significance of c-myc mRNA expression assessed by semi-quantitative RT-PCR in patients with colorectal cancer. Oncol Rep 1998; 5: 441-446.
21. Böckelman C, Koskensalo S, Hagström J, et al. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther 2012; 13: 289-295.
22. Toon CW, Chou A, Clarkson A, et al. Immunohistochemistry for myc predicts survival in colorectal cancer. PLoS One 2014; 9: e87456. DOI: 10.1371/journal.pone.0087456.
23. Smith DR, Myint T, Goh HS. Over-expression of the c-myc proto-oncogene in colorectal carcinoma. Br J Cancer 1993; 68: 407-413.
24. He WL, Weng XT, Wang JL, et al. Association between c-Myc and colorectal cancer prognosis: a meta-analysis. Front Physiol 2018; 9: 1549. DOI: 10.3389/fphys.2018.01549.
25. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-322. DOI: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9.
26. Felthaus O, Ettl T, Gosau M, et al. Cancer stem cell-like cells from a single cell of oral squamous carcinoma cell lines. Biochem Biophys Res Commun 2011; 407: 28-33. DOI: 10.1016/j.bbrc. 2011.02.084.
27. Yoshida GJ, Saya H. Therapeutic strategies targeting cancer stem cells. Cancer Sci 2016; 107: 5-11.
28. Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat 2015; 153: 477-491.
29. Abubakar M, Orr N, Daley F, et al. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res 2016; 18: 104. DOI: 10.1186/s13058-016-0765-6.
30. Burdon T, Smith A, Savatier P. Signalling, cell cycle and pluripotency in embryonic stem cells. Trends Cell Biol 2002; 12: 432-438.
31. Zhou H, Hu YU, Wang W, et al. Expression of Oct 4 is significantly associated with the development and prognosis of colo­rectal cancer. Oncol Lett 2015; 10: 691-696.
32. Moharil RB, Dive A, Khandekar S, Bodhade A. Cancer stem cells: an insight. J Oral Maxillof Pathol 2017; 21: 463. DOI: 10.4103/jomfp.JOMFP_132_16.
33. Liu FS, Hsieh YT, Chen JT, et al. FHIT (fragile histidine triad) gene analysis in cervical intraepithelial neoplasia. Gynecol Oncol 2001; 82: 283-290.
34. Voutsadakis IA. The pluripotency network in colorectal cancer pathogenesis and prognosis: an update. Biomark Med 2018; 12: 653-665.
35. Dai X, Ge J, Wang X, et al. OCT4 regulates epithelial-mesenchymal transition and its knockdown inhibits colorectal cancer cell migration and invasion. Oncol Rep 2013; 29: 155-160.
36. Talebi A, Kianersi K, Beiraghdar M. Comparison of gene expression of SOX2 and OCT4 in normal tissue, polyps, and colon adenocarcinoma using immunohistochemical staining. Adv Biomed Res 2015; 4: 234. DOI: 10.4103/2277-9175.167958.
37. Gwak JM, Kim M, Kim HJ, et al. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance. Oncotarget 2017; 8: 36305-36318.
38. Cheng CC, Shi LH, Wang XJ, et al. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. Int J Oncol 2018; 53: 339-348.
39. Lüscher B, Larsson LG. The basic region/helix–loop–helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation. Oncogene 1999; 18: 2955-2966.
40. Türk Hematoloji Derneği, Klinisyen-Patolog Ortak Lenfoma Kursu, 6-7 Mart 2004, Grand Cevahir Otel, İstanbul.
41. Luo ZW, Zhu MG, Zhang ZQ, et al. Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis. BMC Cancer 2019; 19: 123. DOI: 10.1186/s12885-019-5324-y.
42. Shin IY, Sung NY, Lee YS, et al. The expression of multiple proteins as prognostic factors in colorectal cancer: cathepsin D, p53, COX-2, epidermal growth factor receptor, C-erbB-2, and Ki-67. Gut Liver 2014; 8: 13-23.
43. Reimers MS, Zeestraten EC, van Alphen TC, et al. Combined analysis of biomarkers of proliferation and apoptosis in colon cancer: an immunohistochemistry-based study using tissue microarray. Int J Colorectal Dis 2014; 29: 1043-1052.
44. Melling N, Kowitz CM, Simon R, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol 2016; 69: 209-214.
45. Li L, Bhatia R. Stem cell quiescence. Clin Cancer Res 2011; 17: 4936-4941.
46. Cheung TH, Rando TA. Molecular regulation of stem cell quiescence. Nat Rev Mol Cell Biol 2013; 14: 329-340.
47. Zhou Y, Xia L, Wang H, et al. Cancer stem cells in progression of colorectal cancer. Oncotarget 2018; 9: 33403-33415.
Copyright: © 2024 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.